NasdaqGM:AXSM - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	1,116	324	191	223	12
12/31/2025	671	-16	-45	-16	16
12/31/2024	376	-233	-191	-131	16
3/31/2024	251	-296	-193	-193	N/A
12/31/2023	271	-239	-146	-145	N/A
9/30/2023	223	-202	-143	-142	N/A
6/30/2023	182	-184	-112	-111	N/A
3/31/2023	145	-159	-90	-90	N/A
12/31/2022	50	-187	-117	-117	N/A
9/30/2022	26	-160	-118	-118	N/A
6/30/2022	9	-150	-123	-122	N/A
3/31/2022	N/A	-141	-114	-114	N/A
12/31/2021	N/A	-130	-109	-108	N/A
9/30/2021	N/A	-126	-100	-100	N/A
6/30/2021	N/A	-114	-89	-89	N/A
3/31/2021	N/A	-100	-82	-82	N/A
12/31/2020	N/A	-103	-79	-78	N/A
9/30/2020	N/A	-99	-75	-75	N/A
6/30/2020	N/A	-95	-70	-70	N/A
3/31/2020	N/A	-90	-60	-60	N/A
12/31/2019	N/A	-68	-46	-46	N/A
9/30/2019	N/A	-53	-39	-39	N/A
6/30/2019	N/A	-42	-34	-34	N/A
3/31/2019	N/A	-37	-33	-33	N/A
12/31/2018	N/A	-31	-30	-30	N/A
9/30/2018	N/A	-29	-27	-27	N/A
6/30/2018	N/A	-27	-27	-27	N/A
3/31/2018	N/A	-26	-27	-27	N/A
12/31/2017	N/A	-29	N/A	-26	N/A
9/30/2017	N/A	-29	N/A	-27	N/A
6/30/2017	N/A	-30	N/A	-26	N/A
3/31/2017	N/A	-29	N/A	-24	N/A
12/31/2016	N/A	-27	N/A	-21	N/A
9/30/2016	N/A	-23	N/A	-16	N/A
6/30/2016	N/A	-21	N/A	-13	N/A
3/31/2016	N/A	-16	N/A	-10	N/A
12/31/2015	N/A	-12	N/A	-7	N/A
9/30/2015	N/A	-10	N/A	-7	N/A
6/30/2015	N/A	-6	N/A	-6	N/A
3/31/2015	N/A	-6	N/A	-5	N/A
12/31/2014	N/A	-6	N/A	-5	N/A

アナリストによる今後の成長予測

収入対貯蓄率: AXSMは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.4% ) よりも高い成長率であると考えられます。

収益対市場: AXSM今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: AXSM今後 3 年以内に収益を上げることが予想されます。

収益対市場: AXSMの収益 ( 37.1% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: AXSMの収益 ( 37.1% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: AXSMの自己資本利益率は、3年後には非常に高くなると予測されています ( 63.6 %)。

Axsome Therapeutics 将来の成長

Future 基準チェック /66

主要情報

今後の成長に関する最新情報

Consensus EPS estimates fall by 25%

Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Forecast breakeven date pushed back to 2026

Consensus EPS estimates fall by 21%

Consensus EPS estimates fall by 12%, revenue upgraded

Consensus revenue estimates increase by 45%

Recent updates

Axsome Therapeutics, Inc. Settles Sunosi (solriamfetol) Patent Litigation with Unichem Laboratories Ltd

Consensus EPS estimates fall by 25%

Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments

Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Forecast breakeven date pushed back to 2026

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Axsome Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Axsome Therapeutics, Inc. to Report Q1, 2024 Results on May 06, 2024

COO & Secretary exercised options and sold US$1.9m worth of stock

Axsome Therapeutics, Inc. Initiates Engage Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder

Axsome Therapeutics, Inc. Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients

Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder

Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?

Independent Lead Director notifies of intention to sell stock

Consensus EPS estimates fall by 21%

Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges

Full year 2023 earnings: EPS misses analyst expectations

Axsome Therapeutics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is Still On The Mark Following 27% Share Price Bounce

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

Rosen Law Firm Announces the Reopening of the Lead Plaintiff Appointment Process in a Class Action Against Axsome Therapeutics, Inc. and Certain Officers

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Axsome Therapeutics, Inc. Presents Results of the Accord Trial of AXS-05 in Alzheimer's Disease Agitation at the Clinical Trials on Alzheimer's Disease Agitation at its Clinical Trials on Alzheimer's Disease 2023 Conference

Axsome Therapeutics Appoints Sue Mahony to Its Board of Directors

Axsome Therapeutics Appoints Sue Mahony to Its Board of Directors

Axsome Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Independent Director notifies of intention to sell stock

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

Consensus EPS estimates fall by 12%, revenue upgraded

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Axsome Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Axsome Therapeutics Initiates Focus Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (Adhd) in Adults

Axsome Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Axsome Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Axsome Therapeutics, Inc. to Present New Sunosi Data at Sleep 2023

Consensus revenue estimates increase by 45%

Upgrade: Analysts Just Made A Dazzling Increase To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts

Consensus EPS estimates fall by 27%

Earnings Update: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?

Axsome Therapeutics, Inc. to Report Q4, 2022 Results on Feb 27, 2023

Forecast to breakeven in 2025

Axsome Therapeutics Presents New Data from the Evolve Open-Label Trial Demonstrating Effects of Auvelity® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder At the American College of Neuropsychopharmacology (Acnp) 2022 Annual Meeting

Price target increased to US$109

Axsome Therapeutics, Inc. Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation

Insufficient new directors

Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?

Axsome Therapeutics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Axsome Therapeutics, Inc. Announces Availability of Auvelity, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

No longer forecast to breakeven

Axsome Therapeutics: Clear Path Ahead For AXS07

Axsome Therapeutics, Inc. Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the Sharp Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea

Axsome Therapeutics, Inc. Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting

Axsome to resubmit marketing application for migraine therapy in Q3 2023

Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity

Axsome Therapeutics, Inc. Initiates ADVANCE-2 Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation

Forecast to breakeven in 2024

Axsome Therapeutics Announces Publication of Post-hoc Analysis of Sunosi® Effect on Excessive Daytime Sleepiness in Narcolepsy or Obstructive Sleep Apnea Patients with a History of Depression in the Journal of Psychiatric Research

Axsome Therapeutics Initiates EMERGE Phase 3 Open-Label Trial of AXS-07 for the Acute Treatment of Migraine in Adults with a Prior Inadequate Response to an Oral CGRP Inhibitor

Axsome begins enrolling in late-stage study of migraine drug AXS-07

Price target increased to US$92.93

Axsome Therapeutics Announces FDA Approval of AUVELITY(TM), the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

Axsome gains 19% as FDA approves depression therapy

No longer forecast to breakeven

Axsome Therapeutics Q2 2022 Earnings Preview

Axsome Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Axsome: Breaking Bearish Trend

Consensus forecasts updated